GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (LTS:0NZU) » Definitions » Price-to-Free-Cash-Flow

Zealand Pharma AS (LTS:0NZU) Price-to-Free-Cash-Flow : N/A (As of Oct. 31, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Price-to-Free-Cash-Flow?

As of today (2024-10-31), Zealand Pharma AS's share price is kr814.25. Zealand Pharma AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was kr-8.66. Hence, Zealand Pharma AS's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Zealand Pharma AS's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Zealand Pharma AS's highest Price-to-Free-Cash-Flow Ratio was 90.60. The lowest was 80.08. And the median was 87.78.

LTS:0NZU's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 37.165
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Zealand Pharma AS's Free Cash Flow per Share for the three months ended in Jun. 2024 was kr-3.79. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-8.66.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 24.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 3.80% per year.

During the past 13 years, Zealand Pharma AS's highest 3-Year average Free Cash Flow per Share Growth Rate was 32.10% per year. The lowest was -70.70% per year. And the median was -19.60% per year.


Zealand Pharma AS Price-to-Free-Cash-Flow Historical Data

The historical data trend for Zealand Pharma AS's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Price-to-Free-Cash-Flow Chart

Zealand Pharma AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zealand Pharma AS's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Zealand Pharma AS's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Price-to-Free-Cash-Flow falls into.



Zealand Pharma AS Price-to-Free-Cash-Flow Calculation

Zealand Pharma AS's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=814.25/-8.662
=N/A

Zealand Pharma AS's Share Price of today is kr814.25.
Zealand Pharma AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.66.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Zealand Pharma AS  (LTS:0NZU) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Zealand Pharma AS Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines